Premium
Results of Goeckerman Treatment for Psoriasis in Children: A 21‐Year Retrospective Review
Author(s) -
Kortuem Kimberly R.,
Davis Mark D. P.,
Witman Patricia M.,
McEvoy Marian T.,
Farmer Sara A.
Publication year - 2010
Publication title -
pediatric dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.542
H-Index - 73
eISSN - 1525-1470
pISSN - 0736-8046
DOI - 10.1111/j.1525-1470.2010.01124.x
Subject(s) - psoriasis , medicine , folliculitis , dermatology , adverse effect , retrospective cohort study , medical record , pediatrics , surgery
Goeckerman treatment has been used for the management of widespread psoriasis in children for several decades at Mayo Clinic. We aimed to review our institutional experience with the effectiveness of Goeckerman treatment for psoriasis in children. We retrospectively reviewed the records of pediatric patients who underwent Goeckerman treatment over a 21‐year period (1983–2003). The main outcome measure was improvement in psoriasis. During the study period, 65 children received Goeckerman treatment for predominantly widespread, recalcitrant psoriasis. The mean age was 11.6 years (range, 3 mos to 18 yrs), and the female‐to‐male ratio was 2:1. Psoriasis improved in all patients: 55 patients (85%) had >80% clearance of their psoriasis. The only adverse effect was folliculitis, occurring in 27 patients (42%). Mean duration of follow‐up was 2.6 years (range, 17 days–18.2 yrs); average duration of remission was 2.6 years (range, 2 mos–12.79 yrs). Goeckerman treatment is an effective treatment for widespread psoriasis in children.